Articlenpj health systems2026
National scale up of PROM based monitoring after joint replacement in Germany.
Article in npj health systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patient-reported outcome measures (PROMs) can extend follow-up after joint replacement beyond discharge. Using Germany as a case example, national scalability and its potential impact on cost and health outcomes of a trial-proven PROM-based digital monitoring intervention were assessed. A four-step extrapolation mapped trial tasks and time, removed study-only procedures to derive streamlined delivery models, projected national implementation costs (personnel, licence fees, integration), and modelled population-level effects using trial outcomes and insurance claims. Personnel time decreased from 62 min per patient (trial) to 21 min in a hybrid model that retained limited human touchpoints and to 10 min in an automated model that restricted human involvement to safety-critical interventions, with costs of €158, €133 and €127, respectively. Assuming constant effectiveness, estimated health gains were 0.023-0.025 QALYs per patient with €218-€249 savings, suggesting potential annual national savings of €75-€86 million and a surplus of more than 8200 QALYs. Realised value depends on licence pricing, scalable integration, minimal human touchpoints for engagement and safety, and the transferability of trial effects to streamlined delivery models.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.